Benzoyl peroxide: A review of its current use in the treatment of acne vulgaris

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 15, 2009, Pages 2555-2562

  Sagransky, Matt ^a   Yentzer, Brad A ^a   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Acne vulgaris; Benzoyl peroxide; Combination therapy; Propionibacterium acnes

Indexed keywords

ADAPALENE; ANTIBIOTIC AGENT; BENZOIC ACID; BENZOYL PEROXIDE; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; HYDROGEN PEROXIDE; KERATOLYTIC AGENT; REACTIVE OXYGEN METABOLITE; RETINOIC ACID; SALICYLIC ACID; TERBINAFINE; TETRACYCLINE;

ACNE VULGARIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; BURNING SENSATION; CANDIDA ALBICANS; CONCENTRATION RESPONSE; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ERYTHEMA; HUMAN; IN VIVO STUDY; INFORMATION RETRIEVAL; IRRITANT DERMATITIS; KERATOLYSIS; KIDNEY CLEARANCE; MAINTENANCE THERAPY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NEUTROPHIL; PROPIONIBACTERIUM ACNES; PROPIONIBACTERIUM GRANULOSUM; PRURITUS; PSEUDOMONAS AERUGINOSA; REVIEW; SKIN ALLERGY; SKIN EXFOLIATION; SKIN IRRITATION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS HOMINIS; STRATUM CORNEUM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WOUND HEALING;

ACNE VULGARIS; ADMINISTRATION, CUTANEOUS; ANTI-BACTERIAL AGENTS; BENZOYL PEROXIDE; CLINICAL TRIALS AS TOPIC; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; PROPIONIBACTERIUM ACNES;

EID: 70349378474     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903277228     Document Type: Review

References (71)

1. Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol 2007;56:651-663 (Pubitemid 46400177)
2. Leyden JJ, Wortzman M, Baldwin EK. Antibiotic-resistant Propionibacterium acnes suppressed by a benzoyl peroxide cleanser 6%. Cutis 2008;8:417-421
3. Hegemann L, Toso SM, Kitay K, Webster GF. Anti-inflammatory actions of benzoyl peroxide: effects on the generation of reactive oxygen species by leucocytes and the activity of protein kinase C and calmodulin. Br J Dermatol 1994;130:569-575 (Pubitemid 24204691)
4. Waller JM, Dreher F, Behnam S, et al. 'Keratolytic' properties of benzoyl peroxide and retinoic acid resemble salicylic acid in man. Skin Pharmacol Physiol 2006;19:283-289
5. Merker PC. Benzoyl peroxide: a history of early research and researchers. Int J Dermatol 2002;41:185-188
6. Eady EA, Farmery MR, Ross JI, et al. Effects of benzoyl peroxide and erythromycin alone and in combination against antibiotic-sensitive and -resistant skin bacteria from acne patients. Br J Dermatol 1994;131:331-336 (Pubitemid 24290215)
7. Thiboutot DM, Weiss J, Bucko A, et al. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol 2007;57:791-799 (Pubitemid 47553072)
8. Langner A, Chu A, Goulden V, Ambroziak M. A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris. Br J Dermatol 2008;158:122-129 (Pubitemid 350221923)
9. Thiboutot D, Zaenglein A, Weiss J, et al. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol 2008;59:792-800
10. Leyden J, Kaidbey K, Levy SF. The combination formulation of clindamycin 1% plus benzoyl peroxide 5% versus 3 different formulations of topical clindamycin alone in the reduction of Propionibacterium acnes. An in vivo comparative study. Am J Clin Dermatol 2001;2:263-266 (Pubitemid 32738668)
11. Cunliffe WJ, Holland KT, Bojar R, Levy SF. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther 2002;24:1117-1133 (Pubitemid 34833234)
12. Longshore SJ, Hollandsworth K. Acne vulgaris: one treatment does not fit all. Cleve Clin J Med 2003;70:670-680 (Pubitemid 37025097)
13. Pace WE. A benzoyl peroxide-sulfur cream for acne vulgaris. Can Med Assoc J 1965;93:252-254
14. Decker LC, Deuel DM, Sedlock DM. Role of lipids in augmenting the antibacterial activity of benzoyl peroxide against Propionibacterium acnes. Antimicrob Agents Chemother 1989;33:326-330
15. Ibbotson SH, Lambert CR, Moran MN, et al. Benzoyl peroxide increases UVA-induced plasma membrane damage and lipid oxidation in murine leukemia L1210 cells. J Invest Dermatol 1998;110:79-83
16. Cotterill JA. Benzoyl peroxide. Acta Derm Venereol Suppl (Stockh) 1980;89(Suppl):57-63
17. Burkhart CG, Burkhart CN. Treatment of acne vulgaris without antibiotics: tertiary amine-benzoyl peroxide combination vs. benzoyl peroxide alone (Proactiv Solution). Int J Dermatol 2007;46:89-93
18. Worret WI, Fluhr JW. Acne therapy with topical benzoyl peroxide, antibiotics and azelaic acid. J Dtsch Dermatol Ges 2006;4:293-300 (Pubitemid 44139129)
19. Plewig G, Jansen T. Acne and Rosacea. Berlin, New York: Springer, 2000
20. Cove JH, Holland KT. The effect of benzoyl peroxide on cutaneous micro-organisms in vitro. J Appl Bacteriol 1983;54:379-382
21. Webster GF, Leyden JJ, Musson RA, Douglas SD. Susceptibility of Propionibacterium acnes to killing and degradation by human neutrophils and monocytes in vitro. Infect Immun 1985;49:116-121
22. Weiss SJ, LoBuglio AF. Phagocyte-generated oxygen metabolites and cellular injury. Lab Invest 1982;47:5-18
23. Gupta AK, Lynde CW, Kunynetz RA, et al. A randomized, double-blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/ erythromycin 4% in the treatment of moderate acne vulgaris of the face. J Cutan Med Surg 2003;7:31-37
24. Kligman AM, Mills OH, McGinley KJ, Leyden JJ. Acne therapy with tretinoin in combination with antibiotics. Acta Derm Venereol Suppl (Stockh) 1975;74:111-115
25. Cunliffe WJ, Stainton C, Forster RA. Topical benzoyl peroxide increases the sebum excretion rate in patients with acne. Br J Dermatol 1983;109:577-579 (Pubitemid 14245066)
26. Pierard-Franchimont C, Melotte P, Pierard GE. Topical benzoyl peroxide increases the sebum excretion rate. Br J Dermatol 1984;110:506
27. Taylor GA, Shalita AR. Benzoyl peroxide-based combination therapies for acne vulgaris: a comparative review. Am J Clin Dermatol 2004;5:261-265 (Pubitemid 39127968)
28. Nacht S, Yeung D, Beasley JN Jr, et al. Benzoyl peroxide: percutaneous penetration and metabolic disposition. J Am Acad Dermatol 1981;4:31-37 (Pubitemid 11137313)
29. Yeung D, Nacht S, Bucks D, Maibach HI. Benzoyl peroxide: percutaneous penetration and metabolic disposition. II. Effect of concentration. J Am Acad Dermatol 1983;9:920-924 (Pubitemid 14206986)
30. Simonart T. Antibiotic-resistant acne: lessons from good sense. Br J Dermatol 2004;150:369-370 (Pubitemid 38352483)
31. Ross JI, Snelling AM, Carnegie E, et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol 2003;148:467-478
32. Eady EA, Cove JH, Holland KT, Cunliffe WJ. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 1989;121:51-57
33. Leyden JJ, McGinley KJ, Cavalieri S, et al. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 1983;8:41-45 (Pubitemid 13221137)
34. Cunliffe WJ. Propionibacterium-acnes resistance and its clinical relevance. J Dermatolog Treat 1995;6:S3-4
35. Eady EA, Gloor M, Leyden JJ. Propionibacterium acnes resistance: a worldwide problem. Dermatology 2003;206:54-56 (Pubitemid 36164666)
36. Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the global alliance to improve outcomes in acne group. J Am Acad Dermatol 2009;60(Suppl 5):S1-50
37. Mills O Jr, Thornsberry C, Cardin CW, et al. Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle. Acta Derm Venereol 2002;82:260-265 (Pubitemid 35015045)
38. Mills OH Jr, Kligman AM, Pochi P, Comite H. Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol 1986;25:664-667 (Pubitemid 17210594)
39. Goulden V. Guidelines for the management of acne vulgaris in adolescents. Paediatr Drugs 2003;5:301-313 (Pubitemid 36629713)
40. Mareledwane NG. A randomized, open-label, comparative study of oral doxycycline 100 mg vs. 5% topical benzoyl peroxide in the treatment of mild to moderate acne vulgaris. Int J Dermatol 2006;45:1438-1439
41. Gans EH, Kligman AM. Comparative efficacy of clindamycin and benzoyl peroxide for in vivo suppression of Propionibacterium acnes. J Dermatolog Treat 2002;13:107-110
42. Farmery MR, Jines CE, Eady EA, et al. In vitro activity of azelaic acid, benzoyl peroxide and zinc acetate against antibiotic-resistant propionibacteria from acne patients. J Dermatolog Treat 1994;5:63-65
43. Kligman AM. Comparison of a topical benzoyl peroxide gel, oral minocycline, oral doxycycline and a combination for suppression of P-acnes in acne patients. J Dermatolog Treat 1998;9:187-191
44. do Nascimento LV, Guedes AC, Magalhaes GM, et al. Single-blind and comparative clinical study of the efficacy and safety of benzoyl peroxide 4% gel (BID) and adapalene 0.1% Gel (QD) in the treatment of acne vulgaris for 11 weeks. J Dermatolog Treat 2003;14:166-171
45. Korkut C, Piskin S. Benzoyl peroxide, adapalene, and their combination in the treatment of acne vulgaris. J Dermatol 2005;32:169-173 (Pubitemid 40502415)
46. Burkhart CN, Specht K, Neckers D. Synergistic activity of benzoyl peroxide and erythromycin. Skin Pharmacol Appl Skin Physiol 2000;13:292-296 (Pubitemid 30666028)
47. Weiss JS. Current options for the topical treatment of acne vulgaris. Pediatr Dermatol 1997;14:480-488 (Pubitemid 28012033)
48. Dosik JS, Vamvakias G. Comparative irritation potential of two combination acne products: a randomized controlled, subject- and evaluator-blind, comparative study in healthy volunteers. Am J Clin Dermatol 2008;9:313-317
49. Ko HC, Song M, Seo SH, et al. Prospective, open-label, comparative study of clindamycin 1%/benzoyl peroxide 5% gel with adapalene 0.1% gel in Asian acne patients: efficacy and tolerability. J Eur Acad Dermatol Venereol 2009;23:245-250
50. Dreno B, Reynaud A, Moyse D, et al. Erythromycin-resistance of cutaneous bacterial flora in acne. Eur J Dermatol 2001;11:549-553 (Pubitemid 33044454)
51. Chalker DK, Shalita A, Smith JG Jr, Swann RW. A double-blind study of the effectiveness of a 3%erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. J Am Acad Dermatol 1983;9:933-936 (Pubitemid 14206988)
52. Burkhart CG, Burkhart CN, Isham N. Synergistic antimicrobial activity by combining an allylamine with benzoyl peroxide with expanded coverage against yeast and bacterial species. Br J Dermatol 2006;154:341-344 (Pubitemid 43382708)
53. Pariser DM, Westmoreland P, Morris A, et al. Long-term safety and efficacy of a unique fixed-dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% for the treatment of acne vulgaris. J Drugs Dermatol 2007;6:899-905
54. Nyirady J, Lucas C, Yusuf M, et al. The stability of tretinoin in tretinoin gel microsphere 0.1%. Cutis 2002;70:295-298 (Pubitemid 41750803)
55. Cunliffe WJ, Burke B. Benzoyl peroxide: lack of sensitization. Acta Derm Venereol 1982;62:458-459
56. Eady EA, Cove JH, Joanes DN, Cunliffe W. Topical antibiotics for the treatment of acne vulgaris: a critical evaluation of the literature on their clinical benefit and comparative efficacy. J Dermatolog Treat 1990;1:215-226 (Pubitemid 20337502)
57. Bojar RA, Cunliffe WJ, Holland KT. The short-term treatment of acne vulgaris with benzoyl peroxide: effects on the surface and follicular cutaneous microflora. Br J Dermatol 1995;132:204-208
58. Brown SK, Shalita AR. Acne vulgaris. Lancet 1998;351:1871-1876
59. Fyrand O, Jakobsen HB. Water-based versus alcohol-based benzoyl peroxide preparations in the treatment of acne vulgaris. Dermatologica 1986;172:263-267 (Pubitemid 16095697)
60. Weinberg JM. The utility of benzoyl peroxide in hydrophase base (Brevoxyl) in the treatment of acne vulgaris. J Drugs Dermatol 2006;5:344-349
61. Embil K, Nacht S. The Microsponge Delivery System (MDS): a topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives. J Microencapsul 1996;13:575-588 (Pubitemid 26283810)
62. Jelvehgari M, Siahi-Shadbad MR, Azarmi S, et al. The microsponge delivery system of benzoyl peroxide: preparation, characterization and release studies. Int J Pharm 2006;308:124-132 (Pubitemid 43097243)
63. Ross JI, Eady EA, Cove JH, et al. Clinical resistance to erythromycin and clindamycin in cutaneous propionibacteria isolated from acne patients is associated with mutations in 23S rRNA. Antimicrob Agents Chemother 1997;41:1162-1165
64. Coates P, Vyakrnam S, Eady EA, et al. Prevalence of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distribution study. Br J Dermatol 2002;146:840-848 (Pubitemid 34539195)
65. Schlessinger J, Menter A, Gold M, et al. Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris. J Drugs Dermatol 2007;6:607-615
66. Carroll CL, Feldman SR, Camacho FT, Balkrishnan R. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol 2004;151:895-897 (Pubitemid 39482127)
67. Meredith PA. Therapeutic implications of drug 'holidays'. Eur Heart J 1996;17(Suppl A):21-24
68. Eisen SA, Woodward RS, Miller D, et al. The effect of medication compliance on the control of hypertension. J Gen Intern Med 1987;2:298-305
69. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30 (Pubitemid 30432540)
70. Parsons RJ, Wright ND, Wilson LS. Evaluation of patients' compliance with medical practitioners' prescriptions: university health center experience. J Am Coll Health Assoc 1980;28:342-345
71. Ozolins M, Eady EA, Avery AJ, et al. Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial. Lancet 2004;364:2188-2195 (Pubitemid 40018448)